Profile data is unavailable for this security.
About the company
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
- Revenue in USD (TTM)80.89m
- Net income in USD-144.73m
- Incorporated2009
- Employees284.00
- LocationNurix Therapeutics Inc1700 Owens St Ste 205SAN FRANCISCO 94158-0006United StatesUSA
- Phone+1 (415) 660-5320
- Fax+1 (415) 525-4200
- Websitehttps://www.nurixtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Y-mAbs Therapeutics Inc | 84.82m | -21.43m | 665.85m | 100.00 | -- | 6.58 | -- | 7.85 | -0.4909 | -0.4909 | 1.94 | 2.31 | 0.6299 | 1.93 | 4.85 | 848,190.00 | -15.91 | -44.23 | -19.40 | -50.45 | 86.60 | -- | -25.26 | -181.13 | 5.27 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Phibro Animal Health Corp | 982.01m | 14.80m | 676.41m | 1.92k | 45.71 | 2.50 | 13.63 | 0.6888 | 0.3654 | 0.3654 | 24.24 | 6.69 | 1.02 | 2.37 | 6.49 | 511,465.60 | 1.53 | 5.46 | 1.87 | 6.83 | 30.43 | 31.41 | 1.51 | 5.11 | 1.60 | 2.50 | 0.6369 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
Mind Medicine (MindMed) Inc | 0.00 | -95.73m | 684.23m | 57.00 | -- | 5.01 | -- | -- | -2.45 | -2.45 | 0.00 | 1.90 | 0.00 | -- | -- | 0.00 | -65.01 | -- | -78.34 | -- | -- | -- | -- | -- | -- | -- | 0.1531 | -- | -- | -- | -68.55 | -- | -- | -- |
Disc Medicine Inc | 0.00 | -76.43m | 687.12m | 74.00 | -- | 1.97 | -- | -- | -3.49 | -3.49 | 0.00 | 14.17 | 0.00 | -- | -- | 0.00 | -26.90 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Arcturus Therapeutics Holdings Inc | 166.80m | -29.73m | 688.22m | 180.00 | -- | 2.46 | -- | 4.13 | -1.16 | -1.16 | 6.23 | 10.38 | 0.3792 | -- | 9.58 | 926,661.10 | -6.76 | -19.66 | -8.86 | -24.90 | -- | -- | -17.82 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
enGene Holdings Inc | 0.00 | -106.80m | 701.20m | 33.00 | -- | 5.91 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
Nurix Therapeutics Inc | 80.89m | -144.73m | 712.83m | 284.00 | -- | 3.50 | -- | 8.81 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Pliant Therapeutics Inc | 1.58m | -161.34m | 712.97m | 158.00 | -- | 1.50 | -- | 451.25 | -2.75 | -2.75 | 0.0269 | 7.90 | 0.0037 | -- | 1.59 | 10,000.00 | -37.40 | -33.24 | -39.82 | -35.39 | -- | -- | -10,211.14 | -360.29 | -- | -- | 0.0208 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Evolus Inc | 202.09m | -61.69m | 722.38m | 273.00 | -- | -- | -- | 3.57 | -1.08 | -1.08 | 3.55 | -0.3578 | 1.10 | 4.12 | 7.63 | 740,238.10 | -33.62 | -40.92 | -45.33 | -59.74 | 69.54 | 65.43 | -30.52 | -80.46 | 2.10 | -3.47 | 1.21 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
Aurinia Pharmaceuticals Inc | 175.51m | -78.02m | 727.97m | 300.00 | -- | 1.94 | -- | 4.15 | -0.5454 | -0.5454 | 1.23 | 2.63 | 0.3445 | 0.439 | 9.34 | 585,043.30 | -15.31 | -25.97 | -17.42 | -28.24 | 91.94 | -- | -44.45 | -137.64 | 4.99 | -- | 0.1925 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
Ocular Therapeutix Inc | 58.44m | -80.74m | 733.40m | 267.00 | -- | 5.98 | -- | 12.55 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
Nuvation Bio Inc | 0.00 | -75.80m | 737.61m | 51.00 | -- | 1.08 | -- | -- | -0.3463 | -0.3463 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -11.72 | -16.27 | -11.97 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
CARGO Therapeutics Inc | 0.00 | -98.15m | 751.94m | 116.00 | -- | 1.94 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
Regenxbio Inc | 90.24m | -263.49m | 752.81m | 344.00 | -- | 2.17 | -- | 8.34 | -6.03 | -6.03 | 2.06 | 7.08 | 0.1283 | -- | 3.41 | 262,331.40 | -37.45 | -16.75 | -45.96 | -19.08 | 58.76 | 78.27 | -291.99 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
Holder | Shares | % Held |
---|---|---|
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.90m | 7.99% |
Baker Bros. Advisors LPas of 31 Dec 2023 | 3.88m | 7.94% |
Redmile Group LLCas of 31 Dec 2023 | 3.26m | 6.66% |
Deep Track Capital LPas of 31 Dec 2023 | 3.00m | 6.13% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 2.96m | 6.06% |
ARK Investment Management LLCas of 31 Mar 2024 | 2.64m | 5.39% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.56m | 5.23% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.33m | 4.77% |
Wasatch Advisors, Inc.as of 31 Mar 2024 | 1.24m | 2.53% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.08m | 2.21% |